Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

semaglutide

- PMLiVE

AstraZeneca launches diabetes portal in Germany

Zuckerkrank.de is designed to educate patients and families

- PMLiVE

FDA approves J&J’s diabetes combo

Invokamet combines Invokana and metformin to help reduce blood sugar

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Community pharmacies central to diabetes fight in UK

Risk assessments can help identify people at risk of developing condition

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

- PMLiVE

ADA: Merck launches registry for type 2 diabetes

Will collect information from 20,000 patients across four countries

- PMLiVE

Invokana set for NICE recommendation

Janssen drug will provide another treatment option in diabetes

- PMLiVE

Novo Nordisk: Tresiba makes a solid start

Long-acting insulin capturing share of diabetes market

EU flag

J&J wins EU approval for diabetes combo

Vokanamet combines Invokana and metformin

- PMLiVE

Novo Nordisk chooses Mexico to launch urban diabetes plan

‘Cities Changing Diabetes’ partnership programme launches in Mexico City before global roll out

- PMLiVE

Novo Nordisk will build $100m facility in Denmark

Bagsvaerd site will support growing diabetes pipeline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links